Effectiveness of Vitamin D Supplementation on the Outcome of Pulmonary Tuberculosis Treatment in Adults: A Meta-Analysis of Randomized Controlled Trials
Tuberculosis (TB) remains one of the most significant global health challenges, with millions of new cases and deaths reported annually. Despite advancements in treatment and control, the disease continues to pose a substantial burden, particularly in low- and middle-income countries. Vitamin D has been implicated in the immune response to Mycobacterium tuberculosis, the causative agent of TB, leading to interest in its potential as an adjunctive therapy. This meta-analysis aims to evaluate the effectiveness of vitamin D supplementation in improving the outcomes of pulmonary tuberculosis (PTB) treatment in adults.
The study systematically reviewed randomized controlled trials (RCTs) from PubMed, Embase, and the Cochrane Central Register of Controlled Trials up to February 8, 2019. The primary outcomes assessed were the time to sputum culture and smear conversion and the proportion of participants with negative sputum culture. Secondary outcomes included clinical response to treatment and adverse events. A random-effects model was used to pool the data, and analysis was performed using RevMan 5.3 software.
Five studies involving a total of 1126 participants were included in the meta-analysis. The results indicated that vitamin D supplementation did not significantly shorten the time to sputum culture and smear conversion (hazard ratio [HR] 1.04, 95% confidence interval [CI] 0.89–1.23, P = 0.60; HR 1.15, 95% CI 0.93–1.41, P = 0.20, respectively). Additionally, there was no significant increase in the proportion of participants with negative sputum culture (relative risk [RR] 1.04, 95% CI 0.97–1.11, P = 0.32).
However, subgroup analyses revealed some notable findings. Vitamin D supplementation significantly reduced the time to sputum culture conversion in participants with the TaqI tt genotype (HR 8.09, 95% CI 1.39–47.09, P = 0.02). Furthermore, it improved the multidrug-resistant (MDR) TB sputum culture conversion rate (RR 2.40, 95% CI 1.11–5.18, P = 0.03). These results suggest that vitamin D may have a beneficial effect in specific subgroups of TB patients.
The secondary outcomes, including body mass index (BMI), radiological examinations, and adverse events such as hypercalcemia and mortality, were not significantly influenced by vitamin D supplementation. The overall quality of evidence for the primary outcomes was moderate, with no significant inconsistency, indirectness, or imprecision. However, the evidence for the subgroup analyses was of lower quality due to the limited number of studies and participants.
The findings of this meta-analysis align with previous research, which has shown mixed results regarding the efficacy of vitamin D in TB treatment. Some studies have reported no significant improvement in sputum conversion rates, while others have suggested potential benefits in specific populations, such as those with MDR-TB or certain genetic polymorphisms. The observed benefits in participants with the TaqI tt genotype highlight the importance of considering genetic factors in the response to vitamin D supplementation.
The mechanisms underlying the potential benefits of vitamin D in TB treatment are thought to involve its role in modulating the immune response. Vitamin D enhances the production of antimicrobial peptides, such as cathelicidin, which can directly inhibit the growth of Mycobacterium tuberculosis. Additionally, it modulates the activity of immune cells, including macrophages and T cells, which play crucial roles in the host defense against TB. The variation in response to vitamin D supplementation may be influenced by genetic polymorphisms in the vitamin D receptor (VDR) gene, which can affect the binding and signaling of vitamin D.
Despite the promising findings in specific subgroups, the overall results of this meta-analysis do not support the routine use of vitamin D supplementation as an adjunctive therapy for PTB in adults. The lack of significant benefits in the general population, combined with the potential for adverse effects such as hypercalcemia, suggests that vitamin D should be used cautiously and in targeted populations. Further research is needed to identify the specific patient populations that may benefit from vitamin D supplementation and to determine the optimal dosing and duration of treatment.
The limitations of this meta-analysis include the small number of studies and participants in the subgroup analyses, which limits the generalizability of the findings. Additionally, the variation in vitamin D dosing and administration schedules across studies may have influenced the results. The quality of evidence for the subgroup analyses was low, highlighting the need for larger, well-designed RCTs to confirm these findings.
In conclusion, vitamin D supplementation does not appear to have a significant beneficial effect on the outcomes of PTB treatment in the general adult population. However, it may accelerate sputum culture conversion in patients with the TaqI tt genotype and improve the MDR-TB sputum culture conversion rate. These findings suggest that vitamin D could be a valuable adjunctive therapy in specific subgroups of TB patients, but further research is needed to confirm these results and to identify the optimal conditions for its use.
doi.org/10.1097/CM9.0000000000000554
Was this helpful?
0 / 0